HER 2/neu is known to be overexpressed in approximately Vb of newly diagnosed breast cancers but has not been examined in the majority of breast cancers that recurred after initial treatment. It was therefore evaluated using two different techniques whether the HER 2/neu product in the plasma (measured by EIA technique) and overexpression of the HER 2/neu oncogene (detected by semiquantative differential PCR) can be used as a prognostic marker, as a too] for detecting minimal residual disease after chemotherapy and also as a marker for treatment outcome. Plasma and peripheral blood samples were analyzed prior to treatment, during chemotherapy and after high-dose chemotherapy. The breast cancer patients were stratified for bone marrow involvement. Our results show a correlation between the amount of HER 2/neu protein product detected in the peripheral blood, the overexpression of the HER 2/neu in the peripheral blood cell population and the involvement of the patient's bone marrow. The study is ongoing and correlation between treatment outcomes and survival of over 32 patients is evaluated.
|Original language||English (US)|
|Number of pages||1|
|State||Published - Dec 1 1996|
ASJC Scopus subject areas
- Molecular Biology
- Cell Biology
- Cancer Research